Kura Oncology has launched KOMZIFTI™ (ziftomenib), the first oral menin inhibitor for R/R NPM1-mutated AML, with $2.1 million in net product revenue. The company is set for progress in 2026 with a deep pipeline of therapies. KOMZIFTI gained FDA approval in November 2025 and was added to NCCN guidelines. Recent data from ASH 2025 showed favorable results for ziftomenib combinations. Key milestones for 2026 include accelerating KOMZIFTI uptake and advancing ziftomenib development in various AML settings. Kura Oncology is focused on precision medicines for cancer treatment and continues to innovate in the field.

Read more at GlobeNewswire: Kura Oncology Highlights Recent Accomplishments,